Keryx Biopharma (KERX) Prices 8.23M Offering at $8.49/Share

January 31, 2013 6:53 AM EST Send to a Friend
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) announced the pricing of its previously announced underwritten public offering of common stock consisting of 8,234,000 shares at $8.49 per share. In connection with this offering, Keryx granted to the underwriters a 30-day option to purchase 1,235,100 additional shares of common stock. We intend to use the net proceeds from the sale of our common stock to fund pre-launch/launch inventory build-up and select pre-commercial/commercial activities related to Zerenex, and other general corporate purposes.

J.P. Morgan Securities LLC is acting as sole book-running manager in the offering. The co-managers for the offering are Barclays Capital Inc., Citigroup, Oppenheimer & Co. Inc., Stifel Nicolaus Weisel, JMP Securities LLC, Roth Capital Partners, LLC, Brean Capital, LLC and Ladenburg Thalmann & Co. Inc. Burrill Securities LLC, Dawson James Securities, Inc., Maxim Group LLC, MLV & Co. LLC and Trout Capital LLC are acting as advisors to the company.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Equity Offerings

Related Entities

Stifel Nicolaus, JPMorgan, Citi, Roth Capital, JMP Securities, Barclays, Maxim Group, Ladenburg Thalmann Financial Services

Add Your Comment